Brentuximab vedotin (Adcetris®), directed against CD30, was approved for the treatment of certain forms of lymphoproliferative syndromes expressing CD30 including Hodgkin’s disease. This evidence concerns the gene TNFRSF8 and Hodgkins lymphoma.